

Announcement of Organizational and Personnel Changes

Systemex Corporation (HQ: Kobe, Japan; President: Hisashi Ietsugu) announced today its decision to implement organizational and personnel changes, effective April 1, 2011, as detailed below.

The Company aims by these changes to strengthen the business planning and promotion structure and manufacturing functions, thereby propelling the Group to further growth in emerging markets and non-hematology^{*1} and other fields.

1. Organizational Changes

(1) Strengthen business planning and promotion structure

- a) Strengthen planning and promotion of strategies for emerging markets
 - To promote strategic planning and alliances in emerging markets where growth is anticipated, the Business Development Group and the Alliance Group will be consolidated, enabling the IVD Business Development Div. to respond with enhanced agility to changes in the operating environment.
- b) Strengthen structure to develop Life Science business
 - In addition to marketing existing products, the Clinical Assay Business Group will be established to develop the lab assay business. Also, the Business Development Group will be created to integrate planning and promotion of business involving existing products and lab assays.
- c) Strengthen structure to develop and promote new business
 - The New Business Development Div. will be formed to facilitate the search for new businesses and promote developments that will expand the Group's business beyond the limitations of organic growth through M&A and other opportunities.

(2) Strengthen manufacturing

- a) Reorganize R&D structure according to development stages and fields
 - To enhance the efficiency of R&D activities, practical development functions, which were previously separated into the research division and the development division, will be consolidated into the Technology Development Div.
 - Product Development Div. 1 and Product Development Div. 2 will be established, reorganizing product development by field of testing, such as the hematology and non-hematology^{*1} fields. This will promote the integration of instrument and reagent development and enhance its specialization and speed.
- b) Reorganize the Research Groups at the Central Research Laboratories
 - Research Groups will be reorganized along thematic lines, such as cellular analysis and gene analysis, and research will be conducted toward their application to leading-edge technologies and clinical testing.

- c) Strengthen technological capabilities and production functions
- The Engineering Development Center will be established in the Manufacturing Management Div. to bolster our ability to develop elemental technology that will strengthen our technological capabilities and accelerate product development catered to emerging markets.
 - Within the Manufacturing Management Div., the roles of Production Engineering Dept. 1 and Production Engineering Dept. 2 will be reorganized as the Product Engineering Dept. and the Process Engineering Dept.

(3) Strengthen corporate functions

- To foster more aggressive efforts toward corporate social responsibility, the CSR Div. will be established to manage the CSR Promotion Dept. and the Risk Management Dept., promoting CSR activities incorporating risk management.
- To bolster groupwide quality assurance to meet the demands posed by the expansion of operations geographically and into additional fields of business, the Regulatory Affairs and Vigilance Dept. will be established within the Regulatory Affairs and Quality Assurance Div. to conform with the Pharmaceutical Affairs Law and other regulations and integrate the management of market safety information.

(4) Others

- The Intellectual Property Div. will be merged with the R&D Strategic Planning Div. to help integrate intellectual property and technology strategies.
- Now that global BIS^{*2} implementation has been completed, the BIS Project Management Dept. will be closed.

*1 Non-hematology: *in vitro* diagnostics fields excluding hematology but including hemostasis, immunochemistry, urinalysis, clinical chemistry and others.

*2 BIS: Acronym for Business Infrastructure Standardization, meaning the standardization of core groupwide operations, not limited to accounting but including such operations as production and supply chain management.

2. Personnel Changes and Appointments

(1) Managing Officer (Newly-appointed)

	New Position	Current Position
Masayoshi Hayashi	Member of the Managing Board and Executive Officer Senior Managing Director	Member of the Managing Board and Executive Officer Managing Director

(2) Deputy Acting Executive Officers (Newly-appointed)

	New Position	Current Position
Michiaki Ishida	Executive Officer Deputy in charge of; SCM Div. Manufacturing Management Div. Instrument Production Div.	Executive Officer Executive Vice President of Manufacturing Management
Takashi Goda	Executive Officer Deputy in charge of; Business Management (Japan) Div. Sales & Marketing / East Japan Div. Sales & Marketing / West Japan Div.	Executive Officer Executive Vice President of Business Management (Japan) President of Sysmex TMC Co., Ltd.

(3) Executive Officers (Newly-appointed)

	New Position	Current Position
Junzo Yamamoto	Executive Officer Executive Vice President of Instrument Production Div.	Executive Vice President of Instrument Production
Kenji Tachibana	Executive Officer Executive Vice President of IVD Business Development Div.	Executive Vice President of International Business Management
Iwane Matsui	Executive Officer Executive Vice President of Corporate Business Planning Div.	Executive Vice President of IVD Business Development BIS Project Management

(4) Retirement of Executive Officers (completion of contract term)

	Positions after conclusion of current positions	Current Position
Takuji Nishino	Advisor	Executive Officer Executive Vice President of Intellectual Property
Katsuo Uhara	President of Sysmex TMC Co., Ltd.	Executive Officer Executive Vice President of SCM
Masami Kitagawa	President of Sysmex International Reagents Co., Ltd.	Executive Officer President of Sysmex International Reagents Co., Ltd.

(5) Changes in operating & functional charges of an Executive Officers

	New Position	Current Position
Kenichi Yukimoto	Member of the Managing Board and Executive Officer Senior Managing Director Assistant to the President In charge of CSR Div.	Member of the Managing Board and Executive Officer Senior Managing Director Assistant to the President In charge of CSR Promotion Div. BIS Project Management
Masayoshi Hayashi	Member of the Managing Board and Executive Officer Senior Managing Director In charge of; Business Management (Japan) Div. Sales & Marketing / East Japan Div. Sales & Marketing / West Japan Div. Scientific Affairs Div. Customer Support Div. Sysmex CNA Co., Ltd. Sysmex TMC. Co.,Ltd. Sysmex bioMerieux Co.,Ltd.	Member of the Managing Board and Executive Officer Managing Director In charge of; Business Management (Japan) Sales & Marketing / East Japan Sales & Marketing / West Japan Scientific Affairs Customer Support Sysmex CNA Co.,Ltd.. Sysmex TMC Co.,Ltd. Sysmex bioMerieux Co.,Ltd.
Koji Tamura	Member of the Managing Board and Executive Officer Managing Director In charge of; IVD Business Development Div. Life Science Business Operations Div. New Business Development Div. Executive Vice President of New Business Development Div.	Member of the Managing Board and Executive Officer Managing Director In charge of; IVD Business Development Life Science Business Development
Mitsuru Watanabe	Member of the Managing Board and Executive Officer In charge of; R&D Strategic Planning Div. Central Research Laboratories Technology Development Div. Product Development Div. 1 Product Development Div. 2	Member of the Managing Board and Executive Officer In charge of; R&D Strategic Planning Intellectual Property Central Research Laboratories Diagnostics System Development Diagnostic Reagent Development Deputy in charge of; Life Science Business Development
Yukio Hamaguchi	Executive Officer Executive Vice President of Technology Development Div.	Executive Officer Executive Vice President of Diagnostics Reagent Development
Kaoru Asano	Executive Officer Executive Vice President of R&D Strategic Planning Div.	Executive Officer Executive Vice President of Central Research Laboratories